Project Details
Description
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with Immune-Mediated Diseases
| Status | Active |
|---|---|
| Effective start/end date | 4/7/25 → 4/6/35 |
Funding
- NKARTA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.